World's First Non-invasive Continuous Glucose Monitor

LIFELEAF® - A Breakthrough Device and Platform for Remote Monitoring of Patients with Cardio-Metabolic Risk Factors

Blood Glucose
Blood Pressure
Oxygen Saturation
Heart Rate
Respiration Rate

Provides accurate and reliable results and patterns to help manage blood glucose and cardio-metabolic health using proprietary AI/ML algorithms.  

Challenges
with current monitoring solutions

Current solutions are not patient,
provider or payor friendly.

Picture10

Invasive & Indiscreet

Patients are less inclined to adopt & stick with solution

Picture11

Requires Significant User Involvement

Patient adherence & reimbursement is low

Picture12

Multiple Devices & Platforms

Patients & providers get frustrated and stop using

Picture13

High Cost

Payors, providers, and patients are hesitant to cover solutions

LIFELEAF® Solution

  • No needles, No cuff

    100% pain free & safe

  • Single device tracking all core bio-markers

    Glucose, Blood Pressure, Heart Rate & Rhythm

  • Continuous passive capture of bio-markers

    Cloud-based data analytics supporting delivery of real-time actionable insights and alerts

  • Game changing benefits to patient and provider with the aid of longitudinal data

    - Patient adopts effective behavior modification
    - Provider determines precise medication dosing

LIFELEAF® Smartwatch

Here are some of the home screens and health screens.

An end-to-end connected & personalized remote monitoring platform

Unlock the Power of LIFELEAF®

Platform providing a continuous 360° view of overall health & wellness

User Friendly Mobile App: Main Flow, Measure & Share Data Flow, Calibration

Led by Passionate & Experienced Team, and Science & Business Advisory Team
  • Artificial Intelligence & Digital Health Experts
  • Strong Clinical Research & Business Expertise

Find Out More

Collaborating Research Institutions

Mayo Clinic (USA), University of California, San Francisco (UCSF), American Metabolic Care and Research Institute (AMCR), and others.

Timeline
  • Product Launch (EU, APAC): Q4 2024
  • U.S. Pilot Studies (RPM): Q2 2025
  • FDA Authorization: Q4 2025
  • U.S. Launch: Q1 2026
Academic Achievements

Abstracts presented at the 2023 Advanced Technologies & Treatments for Diabetes (ATTD) Congress and the European Society of Hypertension (ESH).

Physiological Parameters
  • Blood Glucose
  • Blood Pressure
  • Heart Rate & Heart Rhythm
  • Oxygen Saturation
  • Respiration Rate
LIFELEAF® Specifications
  • Motion Sensor: Accelerometer, Gyroscope
  • Mobile App OS: iOs, Android
  • Weight: 38g
  • Waterproof Rating: IP67
  • Memory: 64MB SRAM
  • Battery: 18hrs of continuous monitoring
  • Bluetooth: BLE 5.0
Patents

LIFEPLUS holds 11 U.S. patents, which EUCRASIA is LIFEPLUS's partner in Asia.

* This product is not a medical device and is intended for health management reference only.
If medical diagnosis or treatment is needed, please consult a healthcare professional.

Join us in redefining innovation.

Contact us to explore opportunities for our groundbreaking smartwatch.

Contact Us

If you’d like to know more about our product, please contact us by filling out the form below.
6F Meisan Takahama Building, 2-12-23 Konan, Minato-ku, Tokyo, Japan